Fingolimod for multiple sclerosis. [N Engl J Med. 2012] - PubMed

loading

[New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod]. [Ideggyogy Sz. 2012]
[New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].
Komoly S. Ideggyogy Sz. 2012 Nov 30; 65(11-12):421-2.
Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration. [N Engl J Med. 2006]
Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
Massberg S, von Andrian UH. N Engl J Med. 2006 Sep 14; 355(11):1088-91.
[A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)]. [Zh Nevrol Psikhiatr Im S S Kor...]
[A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)].
Popova NF. Zh Nevrol Psikhiatr Im S S Korsakova. 2011; 111(2 Pt 2):110-3.
Review [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism]. [Ideggyogy Sz. 2012]
Review [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
Tar L, Vécsei L. Ideggyogy Sz. 2012 Mar 30; 65(3-4):83-100.
Review [New disease-modifying and symptomatic therapies for multiple sclerosis]. [MMW Fortschr Med. 2012]
Review [New disease-modifying and symptomatic therapies for multiple sclerosis].
Weise G, Buttmann M. MMW Fortschr Med. 2012 Apr 19; 154(7):64-6.

Sphingolipids in cardiovascular and cerebrovascular systems: Pathological implications and potential therapeutic targets. [World J Cardiol. 2013]
Sphingolipids in cardiovascular and cerebrovascular systems: Pathological implications and potential therapeutic targets.
Kawabori M, Kacimi R, Karliner JS, Yenari MA. World J Cardiol. 2013 Apr 26; 5(4):75-86.
Fingolimod Phosphate Attenuates Oligomeric Amyloid β-Induced Neurotoxicity via Increased Brain-Derived Neurotrophic Factor Expression in Neurons. [PLoS One. 2013]
Fingolimod Phosphate Attenuates Oligomeric Amyloid β-Induced Neurotoxicity via Increased Brain-Derived Neurotrophic Factor Expression in Neurons.
Doi Y, Takeuchi H, Horiuchi H, Hanyu T, Kawanokuchi J, Jin S, Parajuli B, Sonobe Y, Mizuno T, Suzumura A. PLoS One. 2013; 8(4):e61988. Epub 2013 Apr 12.
Multiple sclerosis and the blood-central nervous system barrier. [Cardiovasc Psychiatry Neurol. ...]
Multiple sclerosis and the blood-central nervous system barrier.
Palmer AM. Cardiovasc Psychiatry Neurol. 2013; 2013:530356. Epub 2013 Jan 15.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Fingolimod for multiple sclerosis.
Fingolimod for multiple sclerosis.
N Engl J Med. 2012 Jan 26 ;366(4):339-47. doi: 10.1056/NEJMct1101691.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed